BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

C4X Discovery: Advancing Drug Discovery with NRF2 Activator Program

by Illia Petrov   •   Jan. 4, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

C4X Discovery Holdings plc (AIM: C4XD), a drug discovery company, recently announced a significant milestone in its partnership with AstraZeneca. The company received an $11 million payment, a testament to the preclinical advancements in its NRF2 Activator program, reflecting a promising start to 2024 for C4XD.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The collaboration between C4X Discovery and AstraZeneca, initiated in November 2022, revolves around the development of C4XD's NRF2 Activator program. As part of the exclusive worldwide license agreement, C4XD initially received a $2 million upfront payment and stands to gain up to $400 million more, contingent on the achievement of various preclinical, clinical, and commercial milestones. Additionally, C4XD is eligible for tiered mid-single digit royalties on future sales of products derived from this collaboration.

AstraZeneca's development of the NRF2 Activator program underlines the program's potential in treating inflammatory and respiratory diseases. The focus is on creating an oral therapy, primarily targeting chronic respiratory diseases. NRF2, known for its challenging nature in drug discovery, plays a critical role in regulating antioxidant response in cells, making it a key target for treating diseases with underlying inflammatory processes.

C4X Discovery

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.